Drug information by public health and regulatory institutions: Results of an 8-country survey in Europe

Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID‐19 pandemic

“…However, in Europe the availability of advanced evidence‐based comparative drug information suitable for the general public is extremely heterogeneous. While regulatory information and safety alerts are available in all European countries, Germany and the United Kingdom stand out by showing an advanced framework of evidence‐based, comparative drug information for both health professionals and for the general population [13]. In the context of the COVID‐19 pandemic, a striking concern is the amount of fake news and misleading information circulating worldwide that profoundly affects public health communication in all countries, as reported in Ireland [14], Italy [15], Japan [16], and India [17].…”

Genèse d’un site d’information sur le bon usage du médicament au cours de la pandémie

“…Elles incluent la nécessité de fournir un service sûr et impartial, devenant ainsi un outil de lutte contre la désinformation. En Europe, avant la pandémie, l’offre fiable, basée sur des données scientifiques de qualité et adaptée au grand public sur les médicaments, était décrite comme hétérogène [14] . Le contexte anxiogène de la crise sanitaire a favorisé la propagation d’infox dans le monde entier.…”

Analysis of adverse drug events as a way to improve cancer patient care

“…More efforts are warranted to enhance protocols that will allow an immediate interface to make ADE management more accessible, better understood, and applied in context 12. To this end, patient safety with prescribed OAAs could be improved by HCPs, patients and technological interplay 4…”